Critically, our detailed analysis demonstrates that Ezh2 functions only as a tumor suppressor during leukemia induction and that its catalytic inhibition does not up-regulate HOX genes during AML maintenance (Table S2). The gene discussed is EZH2; the disease is acute myeloid leukemia.